Accelerator Corp. announces new leadership and renames to Accelerator Life Science Partners – GeekWire - Kendall Mohler 300x300 - Accelerator Corp. announces new leadership and renames to Accelerator Life Science Partners – GeekWire
Accelerator Life Science Partners Chief Development Officer Kendall-Mohler. (Accelerator )

Accelerator Corp., a Seattle-based life sciences investment fund, is making some big changes. The firm announced two additions to its leadership team and also changed its name to Accelerator Life Science Partners.

One of the new additions is former Juno Therapeutics executive Kendall Mohler, who will serve in the new role of chief development officer. Mohler is a biotech and pharmaceutical veteran, who joined Juno in 2013 and served as its chief science officer and later its VP of research. According to his LinkedIn page, he retired from that work earlier this year.

The second addition is longtime biotech finance executive Ian Howes, who will serve as the ’s CFO. Howes has served as a biotech CFO in startups and established companies for the past 26 years, most recently at North Carolina’s Heart Metabolics.

Accelerator Corp. announces new leadership and renames to Accelerator Life Science Partners – GeekWire - Ian Howes 300x300 - Accelerator Corp. announces new leadership and renames to Accelerator Life Science Partners – GeekWire
Accelerator Chief Financial officer Ian Howes. (Accelerator Photo)

“We believe that fostering innovation requires more than providing capital and lab space. It also requires a shared passion for advancing human health and an understanding of how to navigate the complex landscape that such advances often require,” Accelerator CEO Thong Q. Le said in a press release. “The additions of Ken and Ian to our executive team enhances our ability to make that journey — for the benefit of our investors, our portfolio companies and the talented entrepreneurs we work with, and ultimately for patients in need.”

Accelerator’s investors include venture partners and national life science companies, including ARCH Venture Partners, Eli Lilly and Company, Johnson & Johnson Innovation and Pfizer Venture Investments. It has funded 19 companies with $130 million so far, including a $62.8 million fund in 201.

The fund invests in biotech startups, including two in Seattle: Rodeo Therapeutics and Apogen Biotechnologies.



Source link

No tags for this post.

LEAVE A REPLY

Please enter your comment!
Please enter your name here